Connect with us

Hi, what are you looking for?

Jewish Business News

Life science

Billionaire Marius Nacht bets big money on Israeli bio-med

“I’m wishing for the creation of another Teva or another Check Point in healthcare.”



Billionaire Marius Nacht, co-founder of Check Point Software Technologies, Israel’s biggest technology company, is now making a big investment in life sciences.

“I’m wishing for the creation of another Teva or another Check Point in healthcare.” Nacht told Reuters, “We are not here to sell out, we are really here to try … and create a big company in the field of bio-med in Israel.”

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Israeli life science startups raised $975 million in 2015, and $680 million in the first nine months of 2016, according to the Israel Venture Capital (IVC) Research Center.

Nacht’s stake in Check Point is estimated at $1.8 billion, according to Globes. In 2012 Nacht was ranked the 11th richest person in Israel by “Forbes” which said that Nacht and his then-wife Anat Agmon had an estimated net worth of $2.5 billion. The couple divorced that same year.

Israeli Startup DayTwo Uses Poop To Provide Personalized Nutrition

Nacht, who co-founded Check Point with Gil Shwed and Shlomo Kramer in 1993, is raising more than $100 million for a new fund. He is investing tens of millions of dollars of his own money with the help of friends and family, in a dozen startups.

In the biotech area, Nacht has already co-founded DayTwo, an Israeli startup which provides personalized nutrition based on the composition of intestinal bacteria, which is unique to each individual.

Nacht has also invested in Regenera Pharma, which developed a drug from plants that prevents nerve damage in degenerative diseases. Regenera’s product is currently undergoing clinical trials for treatment of the rare optic non-arteritic anterior ischemic optic neuropathy (NAION).

RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.